Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | CTSL | P07711 | 3/20 | 0.37 |
| ▸ | CTSB | P07858 | 3/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26154986 | 0.94 | TACR1 (0.45) | TACR1TSHRCHRM3CTSLCTSB | |
| SCHEMBL17100019 | 0.80 | TSHR (0.52) | TACR1TSHRCHRM3LMNALTA4H | |
| SCHEMBL3490325 | 0.79 | TSHR (0.47) | TACR1TSHRCHRM3LMNA | |
| SCHEMBL19074506 | 0.79 | TSHR (0.47) | TACR1TSHRCTSKLTA4H | |
| SCHEMBL15043681 | 0.78 | TACR1 (0.45) | TACR1TSHRCHRM3LTA4H | |
| SCHEMBL4208040 | 0.76 | TACR1 (0.44) | TACR1TSHRMAOBLMNALTA4H | |
| SCHEMBL21214445 | 0.76 | TACR1 (0.52) | TACR1CTSS | |
| SCHEMBL5722244 | 0.76 | TSHR (0.47) | TACR1TSHRLMNA | |
| SCHEMBL100994 | 0.74 | TACR1 (0.45) | TACR1TSHRCHRM3CTSLCTSB | |
| SCHEMBL15042326 | 0.74 | TACR1 (0.42) | TACR1TSHRCHRM3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CATALANO JOHN G | 2008-03-06 | — | — | US | disclosed |
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CATALANO JOHN G | 2008-03-06 | — | — | US | disclosed |
| US-7282512-B2 | Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282512-B2 | Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-03-10 | — | — | US | disclosed |
| EP-1465862-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003062192-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | CTSK, CTSS, CTSE | TACR1 1802/4885TSHR 3687/4885CHRM3 4059/4885 |
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CTSK, CTSS, CTSE | TACR1 1802/4885TSHR 3687/4885CHRM3 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.